The pulmonary/respiratory drug delivery market was valued at USD 53,018.64 million in 2021 and is expected to reach USD 87,745.62 million by 2029, registering a CAGR of 6.5% during the forecast period of 2022-2029
Crafted by a team of seasoned researchers, forecasters, analysts, and managers, the exceptional Pulmonary/Respiratory Drug Delivery Market research report embodies expertise and innovation. Seamlessly merging proficient capabilities and top-notch resources in research, data collection, development, consulting, evaluation, compliance, and regulatory services, this report stands as a pinnacle in world-class market research. In today's fiercely competitive landscape, staying well-informed about market dynamics is paramount, and this exceptional report is the key to achieving that insight. It meticulously segments markets based on coverage, geographic scope, study duration, currency considerations, and pricing.
Within its comprehensive market overview, this Pulmonary/Respiratory Drug Delivery Market report dissects market drivers, restraints, opportunities, and challenges, offering invaluable insights that empower businesses to make informed decisions. Tailored to cater to customer requirements, this report becomes an invaluable tool in enhancing return on investment (ROI) for businesses. The estimations of Compound Annual Growth Rate (CAGR) values play a pivotal role, aiding businesses in strategic investment planning over the specified period. This Pulmonary/Respiratory Drug Delivery Market research report doesn't just scratch the surface; it conducts a systematic and comprehensive study, presenting factual and statistical insights pertinent to various facets within the marketing domain.
Pulmonary/respiratory drug delivery basically delivers the drugs to the lung to treat respiratory tract diseases. This route is often preferred broadly because of the non-invasive approach, high blood circulation, big surface area for absorption, and permeability rate.
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
Rise in prevalence of chronic diseases such as bronchitis, tuberculosis and chronic obstructive pulmonary disease, is the most significant factor driving the growth for this market. Additionally, the rise in smoking also results in respiratory issues, which is also expected to accelerate the market's overall growth.
The pulmonary/respiratory drug delivery systems are ideal drug approaches compared to conventional drug delivery approaches. There are various limitations associated with traditional therapy such as late-onset of action and low efficacy. Furthermore, the benefits associated with the pulmonary/respiratory drug delivery system, such as the large surface area present in alveolar sacs, high drug loading efficiency and high vascularization which makes lung an appropriate site for drug absorption are expected to boost the market's growth.
The pulmonary/respiratory drug delivery market is segmented on the basis of product, canister type, application, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Chronic Obstructive Pulmonary Disease
- Asthma
- Cystic Fibrosis
The pulmonary/respiratory drug delivery market is analyzed and market size insights and trends are provided by country, product, canister type, application, distribution channel and end user as referenced above..
North America dominates the pulmonary/respiratory drug delivery market because of the presence of major key players and growing demand for diagnostic devices such as PDDS along with the increase in the level of disposable income and surging incidences of various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and others within the region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the growing number of patients who have asthma and allergic rhinitis, surging number of research and development activities and increasing awareness by public-private organizations within the region.
- GlaxoSmithKline plc (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- 3M (U.S.)
- AstraZeneca (U.K.)
- Merck Co., Inc (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Thermo Fisher Scientific Inc (U.S.)
- Bruker (U.S.)
- Abbott (U.S.)
- Novartis AG (Switzerland)
- Clarke International (U.K)
- Koninklijke Philips N.V. (Netherlands)
- Omron Corporation (Japan)
- Briggs Healthcare (U.K)
- Sunovion Pharmaceuticals Inc (U.S.)
- Thorough examination of prevailing market tendencies
- Updates on the latest product advancements and innovations
- Pulmonary | Respiratory Drug Delivery Market's Compound Annual Growth Rate (CAGR) for both historic and forecasted years
- Strategies and activities of prominent players and brands in the field
- Insights into the industry landscape for emerging participants
